CN103298490B - 结合背板胶质乙酰酯酶的抗体 - Google Patents

结合背板胶质乙酰酯酶的抗体 Download PDF

Info

Publication number
CN103298490B
CN103298490B CN201180056452.6A CN201180056452A CN103298490B CN 103298490 B CN103298490 B CN 103298490B CN 201180056452 A CN201180056452 A CN 201180056452A CN 103298490 B CN103298490 B CN 103298490B
Authority
CN
China
Prior art keywords
seq
aminoacid sequence
antibody
notum
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180056452.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN103298490A (zh
Inventor
小罗伯特·约瑟夫·布罗米奇
冯晓
洪锡柱
格雷戈里·兰德斯
刘杰夫
戴维·乔治·波特
戴维·里德·鲍威尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lexicon Pharmaceuticals Inc
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of CN103298490A publication Critical patent/CN103298490A/zh
Application granted granted Critical
Publication of CN103298490B publication Critical patent/CN103298490B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201180056452.6A 2010-11-24 2011-11-22 结合背板胶质乙酰酯酶的抗体 Expired - Fee Related CN103298490B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41692710P 2010-11-24 2010-11-24
US61/416,927 2010-11-24
PCT/US2011/061785 WO2012071381A1 (en) 2010-11-24 2011-11-22 Antibodies to notum pectinacetylesterase

Publications (2)

Publication Number Publication Date
CN103298490A CN103298490A (zh) 2013-09-11
CN103298490B true CN103298490B (zh) 2017-04-26

Family

ID=46146184

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180056452.6A Expired - Fee Related CN103298490B (zh) 2010-11-24 2011-11-22 结合背板胶质乙酰酯酶的抗体

Country Status (21)

Country Link
US (3) US20130302346A1 (enExample)
EP (1) EP2643019B1 (enExample)
JP (1) JP6033229B2 (enExample)
KR (2) KR20180069083A (enExample)
CN (1) CN103298490B (enExample)
AU (1) AU2011332007C1 (enExample)
BR (1) BR112013012858B1 (enExample)
CA (1) CA2817415C (enExample)
CO (1) CO6721048A2 (enExample)
DK (1) DK2643019T3 (enExample)
ES (1) ES2718849T3 (enExample)
HU (1) HUE043576T2 (enExample)
IL (1) IL225876A0 (enExample)
MX (2) MX385858B (enExample)
NZ (1) NZ609501A (enExample)
PL (1) PL2643019T3 (enExample)
PT (1) PT2643019T (enExample)
RU (1) RU2013123793A (enExample)
SG (1) SG189982A1 (enExample)
WO (1) WO2012071381A1 (enExample)
ZA (1) ZA201302983B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013004776A2 (pt) * 2010-08-27 2017-09-19 Stem Centrx Inc moduladores de proteína notum e métodos de uso
MX385858B (es) 2010-11-24 2025-03-18 Lexicon Pharmaceuticals Inc Anticuerpos que se unen a notum pectinacetilesterasa.
DK2663579T3 (en) 2011-01-14 2017-07-31 Univ California THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
US8802365B2 (en) * 2011-03-22 2014-08-12 Whitehead Institute For Biomedical Research Methods for identifying candidate modulators of NOTUM activity
JP6391574B2 (ja) * 2012-08-31 2018-09-26 アルゲン−エックス ビーブイビーエー 種間標的内交差反応性を有する抗体分子を産生する方法
CA2976926A1 (en) 2015-02-19 2016-08-25 Compugen Ltd. Anti-pvrig antibodies and methods of use
WO2020150282A1 (en) * 2019-01-18 2020-07-23 Askgene Pharma Inc. Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis
CN110317271B (zh) * 2019-07-02 2021-04-30 武汉云克隆科技股份有限公司 一种pinp重组抗体的重/轻链可变区及编码基因和重组抗体
AU2021400733A1 (en) * 2020-12-16 2023-07-13 Memorial Sloan Kettering Cancer Center Cd40 binding molecules and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
ES2199935T3 (es) 1991-03-15 2004-03-01 Amgen Inc. Pegilacion de polipeptidos.
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW313568B (enExample) 1994-12-20 1997-08-21 Hoffmann La Roche
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6080576A (en) 1998-03-27 2000-06-27 Lexicon Genetics Incorporated Vectors for gene trapping and gene activation
GB0201808D0 (en) * 2002-01-25 2002-03-13 European Molecular Biology Lab Embl Protein
US20040063924A1 (en) * 2002-01-28 2004-04-01 Y Tom Tang Secreted proteins
EP1652923B1 (en) * 2003-08-08 2011-10-12 Perseus Proteomics Inc. Gene overexpressed in cancer
BR112013004776A2 (pt) * 2010-08-27 2017-09-19 Stem Centrx Inc moduladores de proteína notum e métodos de uso
MX385858B (es) 2010-11-24 2025-03-18 Lexicon Pharmaceuticals Inc Anticuerpos que se unen a notum pectinacetilesterasa.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Human homolog of NOTUM, overexpressed in hepatocellular carcinoma, is regulated transcriptionally by β-catenin/TCF;Torisu Y等;《Cancer Science》;20080421;第99卷(第6期);第1140页右栏第二段、第1142页左栏第二段 *

Also Published As

Publication number Publication date
ZA201302983B (en) 2017-06-28
EP2643019B1 (en) 2019-01-02
MX2013005906A (es) 2013-06-28
CO6721048A2 (es) 2013-07-31
US20190241677A1 (en) 2019-08-08
MX357166B (es) 2018-06-28
DK2643019T3 (en) 2019-04-15
BR112013012858A2 (pt) 2018-09-04
CA2817415A1 (en) 2012-05-31
AU2011332007B2 (en) 2016-11-10
KR20140026334A (ko) 2014-03-05
AU2011332007A1 (en) 2013-05-09
WO2012071381A1 (en) 2012-05-31
JP2014501513A (ja) 2014-01-23
NZ609501A (en) 2014-12-24
MX385858B (es) 2025-03-18
BR112013012858B1 (pt) 2021-12-07
KR20180069083A (ko) 2018-06-22
RU2013123793A (ru) 2014-12-27
US20130302346A1 (en) 2013-11-14
EP2643019A1 (en) 2013-10-02
JP6033229B2 (ja) 2016-11-30
CA2817415C (en) 2020-05-12
SG189982A1 (en) 2013-06-28
ES2718849T3 (es) 2019-07-04
PT2643019T (pt) 2019-04-23
PL2643019T3 (pl) 2019-07-31
AU2011332007C1 (en) 2017-03-02
IL225876A0 (en) 2013-06-27
CN103298490A (zh) 2013-09-11
EP2643019A4 (en) 2014-12-31
HUE043576T2 (hu) 2019-08-28
US20160152731A1 (en) 2016-06-02
US11059907B2 (en) 2021-07-13

Similar Documents

Publication Publication Date Title
CN103298490B (zh) 结合背板胶质乙酰酯酶的抗体
JP2025061682A (ja) 抗ｍｕｃ１６抗体及びその使用
JP6272793B2 (ja) プロガストリンに対するモノクローナル抗体及びその使用
CN110234349A (zh) 特异性地结合人il-15的抗体及其用途
NO334834B1 (no) Anti-alfavbeta6-antistoff, celle som produserer slikt antistoff, samt anvendelse av antistoffet for fremstilling av medikamenter
JP2006517188A (ja) ホスホリパーゼａ２に対する抗体及びその使用
CN109988240B (zh) 抗gpc-3抗体及其用途
JP2025506172A (ja) コロナウイルスを広く標的とするヒトモノクローナル抗体
WO2021063352A1 (zh) 一种抗pd-l1抗原结合蛋白及其应用
CN119161481A (zh) 用于治疗的药剂、用途和方法
CN117157317A (zh) 用于治疗异常子宫出血的IL-11或IL-11Ra的抑制剂
JP2025121919A (ja) アイソフォーム選択的抗ｔｇｆ－ベータ抗体及び使用方法
US20140302050A1 (en) Targeting an amphiregulin-derived cell surface neo-epitope
HK1189166B (en) Antibodies to notum pectinacetylesterase
HK1189166A (en) Antibodies to notum pectinacetylesterase
HK40049635B (en) Anti-pd-l1 antigen binding protein, and application thereof
HK40049635A (en) Anti-pd-l1 antigen binding protein, and application thereof
HK1178183B (en) Monoclonal antibodies to progastrin and their uses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170426

CF01 Termination of patent right due to non-payment of annual fee